Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Genelux Corp (GNLX)

Genelux Corp (GNLX)
2.80 x 1 3.00 x 52
Post-market by (Cboe BZX)
2.94 +0.24 (+8.89%) 04/22/25 [NASDAQ]
2.80 x 1 3.00 x 52
Post-market 2.99 +0.05 (+1.70%) 19:54 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.72
Day High
2.95
Open 2.73
Previous Close 2.70 2.70
Volume 130,300 130,300
Avg Vol 236,460 236,460
Stochastic %K 76.96% 76.96%
Weighted Alpha -36.83 -36.83
5-Day Change +0.52 (+21.49%) +0.52 (+21.49%)
52-Week Range 1.60 - 5.89 1.60 - 5.89
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,431
  • Shares Outstanding, K 34,604
  • Annual Sales, $ 10 K
  • Annual Income, $ -29,870 K
  • EBIT $ -32 M
  • EBITDA $ -32 M
  • 60-Month Beta -0.36
  • Price/Sales 11,376.07
  • Price/Cash Flow N/A
  • Price/Book 3.48

Options Overview Details

View History
  • Implied Volatility 851.54% ( +279.18%)
  • Historical Volatility 93.52%
  • IV Percentile 83%
  • IV Rank 76.99%
  • IV High 1,040.14% on 04/04/25
  • IV Low 220.48% on 02/21/25
  • Put/Call Vol Ratio 35.00
  • Today's Volume 72
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 463
  • Open Int (30-Day) 313

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.25
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +17.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.99 +47.92%
on 04/09/25
Period Open: 3.93
3.96 -25.80%
on 03/24/25
-0.99 (-25.19%)
since 03/21/25
3-Month
1.99 +47.92%
on 04/09/25
Period Open: 3.15
5.89 -50.04%
on 02/12/25
-0.21 (-6.67%)
since 01/22/25
52-Week
1.60 +83.75%
on 08/05/24
Period Open: 3.35
5.89 -50.04%
on 02/12/25
-0.41 (-12.24%)
since 04/22/24

Most Recent Stories

More News
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GNLX : 2.94 (+8.89%)
Employment Reports to Roll Out Next Friday in Both Countries

Employment Reports to Roll Out Next Friday in Both Countries U.S. Monday Featured Earnings ...

PVH : 71.66 (+3.26%)
LIEN : 10.28 (+1.78%)
SPWH : 1.6200 (+1.89%)
CAG : 25.48 (+0.35%)
PRGS : 56.64 (+3.30%)
PENG : 15.79 (+0.51%)
LW : 52.47 (+1.86%)
UNF : 173.04 (+1.39%)
BYRN : 21.13 (+4.81%)
LEVI : 15.47 (+3.00%)
AYI : 232.01 (+1.41%)
NCNO : 23.28 (+0.43%)
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

GNLX : 2.94 (+8.89%)
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

GNLX : 2.94 (+8.89%)
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

GNLX : 2.94 (+8.89%)
Genelux Corporation Announces New Chief Financial Officer

GNLX : 2.94 (+8.89%)
Genelux Corporation CEO Thomas Zindrick to Participate in Virtual Fireside Chat on Clinical Developments for Olvi-Vec

Genelux Corporation's CEO will discuss its lead candidate, Olvi-Vec, in a virtual session on December 16, 2024.Quiver AI SummaryGenelux Corporation, a late clinical-stage immuno-oncology firm, announced...

GNLX : 2.94 (+8.89%)
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

GNLX : 2.94 (+8.89%)
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

GNLX : 2.94 (+8.89%)
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

GNLX : 2.94 (+8.89%)

Business Summary

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary,...

See More

Key Turning Points

3rd Resistance Point 3.25
2nd Resistance Point 3.10
1st Resistance Point 3.02
Last Price 2.94
1st Support Level 2.79
2nd Support Level 2.64
3rd Support Level 2.56

See More

52-Week High 5.89
Fibonacci 61.8% 4.25
Fibonacci 50% 3.74
Fibonacci 38.2% 3.24
Last Price 2.94
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro